{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:38:38Z","timestamp":1770824318977,"version":"3.50.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:p>The national cervical screening programme, CervicalCheck, commenced in Ireland in 2008. Free cervical smear tests are offered to over 1.2 million women aged 25\u201360 every 3 (aged 25\u201344) and 5 (aged 45\u201360) years. The purpose of this paper is to highlight the achievements and document the experience of the first 6 years of a new cervical screening programme. Data were extracted from the programme screening register and colposcopy management systems. SAS, version 9.4 was used for statistical analysis. Over 1.98 million smear tests were performed in over 1 million women during the first 6 years of the programme. Overall 5-year coverage at the end of the sixth year was 77.0%, where coverage is presented for the target population of women aged 25\u201360 years and is adjusted for hysterectomy rates. The numbers of women attending colposcopy increased significantly from 10\u2009000 new patients attending for the first time in the first year to a peak of almost 17\u2009500 in the third year. Increased capacity in colposcopy has delivered significant improvements in waiting times; the percentage of women referred to colposcopy offered an appointment within 8 weeks increased from 41.5% in year 1 to 93.4% in year 4 and has remained above the greater than 90% standard thereafter. The number of biopsies increased markedly, with 33\u2009768 women being diagnosed with cervical intraepithelial neoplasia-grade 2 (CIN2), CIN3 or adenocarcinoma <jats:italic toggle=\"yes\">in situ<\/jats:italic> and 860 being diagnosed with invasive cancer by the end of the sixth year. Lessons from CervicalCheck include the importance of capacity planning in programme delivery. The programme continues to evolve, particularly with the increased usage of human papillomavirus testing and planning for future testing of the human papillomavirus (HPV)-vaccinated cohort.<\/jats:p>","DOI":"10.1097\/cej.0000000000000323","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T13:09:32Z","timestamp":1478610572000},"page":"158-163","source":"Crossref","is-referenced-by-count":7,"title":["Establishment of a national cervical screening programme in Ireland, CervicalCheck: the first 6 years"],"prefix":"10.1097","volume":"27","author":[{"given":"Gr\u00e1inne M.","family":"Flannelly","sequence":"first","affiliation":[{"name":"National Screening Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie T.","family":"Mooney","sequence":"additional","affiliation":[{"name":"National Screening Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e1inne M.","family":"Greehy","sequence":"additional","affiliation":[{"name":"National Screening Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eoin B.","family":"Keogh","sequence":"additional","affiliation":[{"name":"National Screening Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara A.","family":"McNally","sequence":"additional","affiliation":[{"name":"National Screening Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia E.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bpobgyn.2011.05.003","article-title":"Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines","volume":"25","author":"Almonte","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/IGC.0000000000000374","article-title":"Cervical carcinoma in the European Union: an update on disease burden, screening program state of activation, and coverage as of March 2014","volume":"25","author":"Altobelli","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"R3-20230901","first-page":"1","article-title":"Invasive cancer of the cervix in British Columbia: a review of the demography and screening histories of 437 cases seen from 1985\u20131988","volume":"80","author":"Anderson","year":"1992","journal-title":"Obstet Gynecol"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.ejca.2009.07.020","article-title":"Cervical cancer screening policies and coverage in Europe","volume":"45","author":"Anttila","year":"2009","journal-title":"Eur J Cancer"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2003.10.001","article-title":"An analysis of 84\u2009244 patients from the British Columbia cytology-colposcopy program","volume":"92","author":"Benedet","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","article-title":"Human papillomavirus and cervical cancer","volume":"382","author":"Crosbie","year":"2013","journal-title":"Lancet"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"g1458","DOI":"10.1136\/bmj.g1458","article-title":"Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case\u2013control study nested within a population based screening programme in Australia","volume":"348","author":"Crowe","year":"2014","journal-title":"BMJ"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1258\/jms.2010.010033","article-title":"Breast and cervical cancer screening programme implementation in 16 countries","volume":"17","author":"Dowling","year":"2010","journal-title":"J Med Screen"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ejca.2015.03.008","article-title":"Cervical cancer screening in Europe: quality assurance and organisation of programmes","volume":"51","author":"Elfstr\u00f6m","year":"2015","journal-title":"Eur J Cancer"},{"key":"R15-20230901","first-page":"216","article-title":"Age related influence on screening coverage and satisfaction with CervicalCheck","volume":"107","author":"Fitzpatrick","year":"2014","journal-title":"Ir Med J"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1016\/j.vaccine.2007.11.069","article-title":"Cervical cancer screening following prophylactic human papillomavirus vaccination","volume":"26","author":"Franco","year":"2008","journal-title":"Vaccine"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jnci\/djn019","article-title":"Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination","volume":"100","author":"Goldhaber-Fiebert","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R18-20230901","first-page":"403","article-title":"A screening programme for cervical cancer that worked","volume":"7","author":"Hakama","year":"1988","journal-title":"Cancer Surv"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/bjc.1985.241","article-title":"Evaluation of screening programmes for gynaecological cancer","volume":"52","author":"Hakama","year":"1985","journal-title":"Br J Cancer"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ejca.2011.01.008","article-title":"A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow-up in the ARTISTIC trial","volume":"47","author":"Kitchener","year":"2011","journal-title":"Eur J Cancer"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"f4781","DOI":"10.1136\/bmj.f4781","article-title":"Developing role of HPV in cervical cancer prevention","volume":"347","author":"Kitchener","year":"2013","journal-title":"BMJ"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.canep.2013.09.002","article-title":"Trends in incidence of, and mortality from, cervical lesions in Ireland: baseline data for future evaluation of the national cervical screening programme","volume":"37","author":"O\u2019Brien","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2046-4053-2-35","article-title":"Screening for cervical cancer: a systematic review and meta-analysis","volume":"2","author":"Peirson","year":"2013","journal-title":"Syst Rev"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008469-201803000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:03:59Z","timestamp":1693613039000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008469-201803000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000323","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}